The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.

ABSTRACT:

Objectives

Multiorgan abdominal involvement is a hallmark of Cystic fibrosis (CF). The CFAbd-Score^© is the first CF-specific gastrointestinal patient reported outcome-measure (PROM) developed following FDA-guidelines. The PROM has proved to sensitively differentiate people with CF (pwCF) from healthy controls (HC). Furthermore, higher Scores in pwCF are associated with pancreatic insufficiency and history of surgery. Recently, in two large cohorts of pwCF, the PROM revealed significant and clinically meaningful improvements in abdominal symptoms (AS) in pwCF treated with Elexacaftor-Tezacaftor-Ivacaftor (ETI). In the present publication, we aim to validate the translated, linguistically and cross-culturally adapted French version of the CFAbd-Score^©.

Method

SUBMITTER: Sermet-Gaudelus I 

PROVIDER: S-EPMC12780474 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature